论文部分内容阅读
目的:研究拉米夫定(LAM)与干扰素(IFNα)联合用药与单独用药治疗慢性乙型肝炎的疗效。方法:将180例慢性乙型肝炎患者按1∶1∶1比例随机分为3组:联合组予LAM和IFNα-2b治疗;LAM组单予LAM治疗;IFN组单予IFN治疗,疗程均1 a。结果:治疗1 a后,LAM组和IFN组血清HBeAg/抗HBe转换率和HBV-DNA转阴率均低于联合组(P<0.05)。结论:联合治疗的1 a疗效优于单用组,且能减少病毒YMDD变异。
Objective: To study the efficacy of lamivudine (LAM) combined with interferon (IFNα) in the treatment of chronic hepatitis B. Methods: One hundred and eighty patients with chronic hepatitis B were randomly divided into three groups according to the ratio of 1: 1: 1: LAM and IFNα-2b in combination group, LAM alone in LAM group and IFN alone in IFN group a. Results: After 1 year of treatment, the serum HBeAg / anti-HBe conversion rate and HBV-DNA negative rate in LAM group and IFN group were lower than those in combined group (P <0.05). Conclusion: The combined treatment of 1 a curative effect than single use group, and can reduce the virus YMDD mutation.